Breakthrough Therapy Designation Since 2020: Representative Approvals and What the Designation Changes
For teams deciding whether to pursue Breakthrough Therapy Designation, the practical question is what BTD actually changes in development and review — engagement intensity, timeline expectations, and interaction with other expedited pathways — rather than treating the designation as an automatic outcome advantage.
The analysis below looks at representative BTD-bearing approvals since 2020, how the designation interacts with Priority Review and accelerated approval, and what the public review record suggests about its effect on process versus evidentiary standards.
Want to ask Rhizome your own regulatory questions? Try it for free.
Breakthrough Therapy Designation since 2020: representative approvals and what the designation changes
Breakthrough Therapy Designation (BTD) was created to speed development and review of drugs that show, on preliminary clinical evidence, a substantial improvement over available therapy on a clinically significant endpoint. The regulatory question that matters to sponsors is not whether BTD sounds prestigious, but whether it does measurable work: shorter timelines, different evidence packages, better odds of a clean review. The record since 2020 shows that BTD reliably compresses development time and co-travels with Priority Review and accelerated approval, but it does not, on its own, produce stronger pivotal evidence or safer products than comparable non-designated drugs.
What BTD actually changes in the review process
FDA review documents describe BTD as an engagement mechanism rather than a lower evidentiary bar. A breakthrough-designated program is eligible for all Fast Track features plus intensive FDA guidance on an efficient development program beginning as early as Phase 1, an organizational commitment involving senior managers, and rolling review 12. Reviewers point sponsors to the internal "Good Review Practice: Management of Breakthrough Therapy-Designated Drugs and Biologics" and note a willingness to use teleconferences, information requests, and email outside formal meetings 7. In practice, BTD status is cited as the basis for accepting a rolling submission, allowing components of an application to arrive before the full filing deadline 1013.
Two points are commonly misunderstood. First, Priority Review is not automatic with BTD; it remains a separate determination evaluated at the time of the marketing application, even though most breakthrough approvals do in fact carry Priority Review 12. Second, accelerated approval is not conferred by BTD; it is a distinct pathway that many breakthrough programs elect to pursue, particularly in oncology 10.
BTD is also selective, not a rubber stamp. Across FY2018 to FY2021, FDA received far more requests than it granted: 158 received and 71 granted in FY2018 24, 177 and 62 in FY2019 23, 140 and 66 in FY2020 21, and 112 and 52 in FY2021 22. The bulk of activity is at CDER rather than CBER (FY2019: CDER 157 received / 54 granted versus CBER 20 / 8 23; FY2021: CDER 103 / 48 versus CBER 9 / 4 22). In a focused look at non-oncology CDER requests from 2017 to 2019, only 39% were granted, with denials citing insufficient treatment effect, inadequate study design, endpoint problems, safety issues, and reliance on post hoc analyses 71.
Representative breakthrough-designated approvals since 2020
The following approvals are drawn from FDA review documents that explicitly state a Breakthrough Therapy Designation was granted. This is an illustrative set, weighted toward oncology and rare disease, not a complete census.
| Product | Active ingredient | Approved | Review track | Notes |
|---|---|---|---|---|
| Ayvakit 40 | avapritinib | 2020-01-09 | Priority | Unresectable/metastatic GIST (PDGFRA exon 18) |
| Retevmo 47 | selpercatinib | 2020-05-08 | Priority | RET-altered cancers |
| Gavreto 28 | pralsetinib | 2020-09-04 | (not stated) | RET fusion-positive NSCLC |
| Ukoniq 44 | umbralisib | 2021-02-05 | (not stated) | Marginal zone lymphoma; accelerated approval |
| Nulibry 33 | fosdenopterin | 2021-02-26 | Priority | Molybdenum cofactor deficiency type A |
| Jemperli 27 | dostarlimab | 2021-04-22 | Priority | dMMR endometrial cancer; accelerated approval 27 |
| Rybrevant 37 | amivantamab | 2021-05-21 | Priority | EGFR exon 20 insertion NSCLC |
| Korsuva 32 | difelikefalin | 2021-08-23 | Priority | Pruritus in hemodialysis patients |
| Tivdak 26 | tisotumab vedotin | 2021-09-20 | Priority | Recurrent/metastatic cervical cancer |
| Scemblix 48 | asciminib | 2021-10-29 | Priority | Ph+ chronic myeloid leukemia |
| Cibinqo 31 | abrocitinib | 2022-01-14 | Priority | Moderate-to-severe atopic dermatitis |
| Kimmtrak 35 | tebentafusp | 2022-01-25 | Priority | HLA-A*02:01+ uveal melanoma |
| Lytgobi 42 | futibatinib | 2022-09-30 | Standard | Cholangiocarcinoma; accelerated approval 42 |
| Sunlenca 49 | lenacapavir | 2022-12-22 | (not stated) | Multidrug-resistant HIV-1 |
| Augtyro 50 | repotrectinib | 2023-11-15 | (not stated) | ROS1-positive NSCLC |
| Ziihera 43 | zanidatamab | 2024-11-20 | (not stated) | HER2+ biliary tract cancer; accelerated approval 43 |
| Bizengri 34 | zenocutuzumab | 2024-12-04 | (not stated) | NRG1 fusion-positive cancers |
| Ibtrozi 39 | taletrectinib | 2025-06-11 | (not stated) | ROS1-positive NSCLC |
The pattern is consistent with FDA's own description: most designated products are targeted oncology agents or rare-disease therapies, most that report a review track carry Priority Review, and a meaningful share are cleared under accelerated approval.
Did BTD measurably change outcomes? Yes on speed, less so on evidence
Timelines are shorter, and this is the most robust measurable effect. In an oncology comparison, breakthrough indications reached approval with a median clinical development time 3.2 years shorter than non-breakthrough indications (5.6 versus 8.8 years, P=.002) 74. A cross-program analysis of anticancer drugs found BTD-only programs ran 5.6 years versus 7.7 years for drugs with no expedited program 83. These gains reflect both earlier, more intensive FDA interaction and smaller, faster trial programs.
The evidence base is systematically different, not systematically stronger. Breakthrough cancer indications were supported by smaller pivotal trials (median 149 versus 326 patients), were more often single-arm (53% versus 27%), and more often Phase I/II (61% versus 31%) than non-breakthrough indications 74. They were also more likely to be first-in-class (42% versus 28%) 74, which suggests BTD concentrates in genuinely novel programs. Surrogate endpoints dominate: among original breakthrough-designated approvals from 2013 to 2023, 58% of traditional (non-accelerated) approvals rested on pivotal trials with a surrogate primary endpoint, and 100% of the accelerated approvals did 63.
Designation does not translate into demonstrably better efficacy or safety at approval. In a matched cancer-drug cohort, breakthrough drugs were faster to market but their pivotal results were not statistically better: median progression-free survival gain 8.6 versus 4.0 months (P=.11), PFS hazard ratio 0.43 versus 0.51 (P=.28), and response rate 37% versus 39% (P=.74) 62. Serious adverse events (38% versus 36%) and non-progression deaths (6% versus 4%) were similar 62. In other words, the designation marks drugs already viewed as promising and routes them through a faster, more permissive pathway rather than producing better trial outcomes on its own 6271.
BTD travels with accelerated approval and shifts confirmation to the post-market period. In an oncology BTD review, nine breakthrough molecular entities generated ten accelerated approvals 79. Reliance on the post-market period is uneven: among the 2013 to 2023 breakthrough cohort, every accelerated approval carried an FDA-required confirmatory study, but only 4 of 61 traditional approvals based on surrogate endpoints (7%) had such a requirement 63. That gap is the central regulatory-affairs caution: a traditional breakthrough approval on a surrogate endpoint may reach the market with neither randomized outcome data nor a mandated confirmatory trial 63. Confirmatory follow-through across expedited pathways generally is inconsistent, with required post-approval studies often delayed or not initiated 72.
One signal suggests BTD enriches for eventual validation. In an analysis of oncology accelerated approvals, BTD was independently associated with a lower likelihood of subsequent withdrawal (odds ratio 0.26; 95% CI 0.10 to 0.75) 80. Read alongside the evidence-quality findings, this supports the view that FDA's designation decision is a useful early filter for drugs that ultimately hold up, even though the premarket package at the time of approval is often thinner than for non-designated drugs 8063.
Bottom line for regulatory strategy
Since 2020, BTD has been granted to a minority of requesting programs, concentrated at CDER and heavily in targeted oncology and rare disease 232271. Its measurable effects are clearest on process and timing: substantially shorter development times, intensive FDA engagement, rolling review, and near-routine pairing with Priority Review and, frequently, accelerated approval 74831210. Its effect on the strength of the approval package is the opposite of intuition: designated drugs more often rely on small, single-arm, surrogate-endpoint trials and are not shown to be more effective or safer at approval than comparable non-designated drugs 746362. The practical implication is that a BTD is best understood as an accelerant with a deferred evidentiary bill: it moves a promising asset to market faster, but it raises the importance of a credible confirmatory plan, particularly for traditional approvals resting on surrogate endpoints where FDA may not require one 6372.